AU708572B2 - Preparation of (pichia methanolica) auxotrophic mutants - Google Patents
Preparation of (pichia methanolica) auxotrophic mutants Download PDFInfo
- Publication number
- AU708572B2 AU708572B2 AU38856/97A AU3885697A AU708572B2 AU 708572 B2 AU708572 B2 AU 708572B2 AU 38856/97 A AU38856/97 A AU 38856/97A AU 3885697 A AU3885697 A AU 3885697A AU 708572 B2 AU708572 B2 AU 708572B2
- Authority
- AU
- Australia
- Prior art keywords
- cells
- dna
- methanolica
- ade
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241001452677 Ogataea methanolica Species 0.000 title claims description 53
- 238000002360 preparation method Methods 0.000 title description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 75
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 40
- 229910052757 nitrogen Inorganic materials 0.000 claims description 33
- 230000035772 mutation Effects 0.000 claims description 22
- 239000001963 growth medium Substances 0.000 claims description 17
- 229930024421 Adenine Natural products 0.000 claims description 14
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 14
- 229960000643 adenine Drugs 0.000 claims description 14
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 11
- 229960000988 nystatin Drugs 0.000 claims description 11
- 239000002609 medium Substances 0.000 claims description 10
- 230000002950 deficient Effects 0.000 claims description 8
- 230000001413 cellular effect Effects 0.000 claims description 5
- 239000007320 rich medium Substances 0.000 claims description 4
- -1 ammonium ions Chemical class 0.000 claims description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical group N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 3
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 3
- 239000002962 chemical mutagen Substances 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 claims description 3
- PCBMGUSDYHYVBQ-SOOFDHNKSA-N [4-amino-2-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazol-5-yl]phosphonic acid Chemical compound P(=O)(O)(O)C=1N=C(NC1N)C1[C@H](O)[C@H](O)[C@H](O1)CO PCBMGUSDYHYVBQ-SOOFDHNKSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 187
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 147
- 108020004414 DNA Proteins 0.000 description 123
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 41
- 239000008103 glucose Substances 0.000 description 35
- 235000001727 glucose Nutrition 0.000 description 35
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 32
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 32
- 238000003752 polymerase chain reaction Methods 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 22
- 238000004520 electroporation Methods 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- 101150001038 ade gene Proteins 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 17
- 230000009466 transformation Effects 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 230000012010 growth Effects 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 14
- 239000000872 buffer Substances 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 14
- 238000000855 fermentation Methods 0.000 description 14
- 230000004151 fermentation Effects 0.000 description 14
- 239000003550 marker Substances 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 239000012634 fragment Substances 0.000 description 13
- 101100437118 Arabidopsis thaliana AUG1 gene Proteins 0.000 description 12
- 230000001131 transforming effect Effects 0.000 description 12
- 101150096273 ADE2 gene Proteins 0.000 description 11
- 235000020958 biotin Nutrition 0.000 description 11
- 239000011616 biotin Substances 0.000 description 11
- 229960002685 biotin Drugs 0.000 description 11
- 239000008186 active pharmaceutical agent Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 235000013619 trace mineral Nutrition 0.000 description 9
- 239000011573 trace mineral Substances 0.000 description 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 8
- 239000004473 Threonine Substances 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 229960002898 threonine Drugs 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 108010025188 Alcohol oxidase Proteins 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 229960004799 tryptophan Drugs 0.000 description 7
- 101100437119 Arabidopsis thaliana AUG2 gene Proteins 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 101100447572 Schizosaccharomyces pombe (strain 972 / ATCC 24843) gad8 gene Proteins 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000005684 electric field Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 238000007747 plating Methods 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000006152 selective media Substances 0.000 description 5
- 229960002920 sorbitol Drugs 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 150000008575 L-amino acids Chemical class 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 3
- 108020004638 Circular DNA Proteins 0.000 description 3
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 3
- 241000235058 Komagataella pastoris Species 0.000 description 3
- 241000320412 Ogataea angusta Species 0.000 description 3
- 241000235648 Pichia Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 101150050575 URA3 gene Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000012807 shake-flask culturing Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108010082737 zymolyase Proteins 0.000 description 3
- SEHFUALWMUWDKS-UHFFFAOYSA-N 5-fluoroorotic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1F SEHFUALWMUWDKS-UHFFFAOYSA-N 0.000 description 2
- 101150091656 AUG2 gene Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 102100035882 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 2
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 2
- 108010067193 Formaldehyde transketolase Proteins 0.000 description 2
- 108090000698 Formate Dehydrogenases Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102100027330 Phosphoribosylaminoimidazole carboxylase Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- MFPODHWDVFPSKC-BTVCFUMJSA-N methanol;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O MFPODHWDVFPSKC-BTVCFUMJSA-N 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 231100000707 mutagenic chemical Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 108010035774 phosphoribosylaminoimidazole carboxylase Proteins 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000754 repressing effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 101150061183 AOX1 gene Proteins 0.000 description 1
- 101150034952 AUG1 gene Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 102100029516 Basic salivary proline-rich protein 1 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000005575 Cellulases Human genes 0.000 description 1
- 108010084185 Cellulases Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102100040606 Dermatan-sulfate epimerase Human genes 0.000 description 1
- 241001057440 Didion Species 0.000 description 1
- JYGLAHSAISAEAL-UHFFFAOYSA-N Diphenadione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 JYGLAHSAISAEAL-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241001288713 Escherichia coli MC1061 Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001125486 Homo sapiens Basic salivary proline-rich protein 1 Proteins 0.000 description 1
- 101000816698 Homo sapiens Dermatan-sulfate epimerase Proteins 0.000 description 1
- 101100223310 Homo sapiens GAD1 gene Proteins 0.000 description 1
- 101100223318 Homo sapiens GAD2 gene Proteins 0.000 description 1
- 101000955035 Homo sapiens Homeobox protein MOX-1 Proteins 0.000 description 1
- 101001108219 Homo sapiens NADPH oxidase 1 Proteins 0.000 description 1
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100243377 Mus musculus Pepd gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 101150029183 PEP4 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 108700025832 Serum Response Element Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 101150025342 UGI gene Proteins 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000222124 [Candida] boidinii Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000003262 industrial enzyme Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940049018 mycostatin Drugs 0.000 description 1
- 235000021048 nutrient requirements Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000011172 small scale experimental method Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
WO 98/02536 PCT/US97/12582 Description PREPARATION OF PICHIA METHANOLICA AUXOTROPHIC
MUTANTS
Background of the Invention Methylotrophic yeasts are those yeasts that are able to utilize methanol as a sole source of carbon and energy. Species of yeasts that have the biochemical pathways necessary for methanol utilization are classified in four genera. Hansenula. Pichia. Candida. and Torulopsis.
These genera are somewhat artificial, having been based on cell morphology and growth characteristics, and do not reflect close genetic relationships (Billon-Grand, Mvcotaxon 35:201-204, 1989; Kurtzman, Mvcologia 84:72-76. 1992). Furthermore. not all species within these genera are capable of utilizing methanol as a source of carbon and energy. As a consequence of this classification, there are great differences in physiology and metabolism between individual species of a genus.
Methylotrophic yeasts are attractive candidates for use in recombinant protein production systems. Some methylotrophic yeasts have been shown to grow rapidly to high biomass on minimal defined media. Certain genes of methylotrophic yeasts are tightly regulated and highly expressed under induced or de-repressed conditions, suggesting that promoters of these genes might be useful for producing polypeptides of commercial value. See, for example, Faber et al., Yeast 11:1331. 1995; Romanos et al., Yeast 8:423, 1992; and Cregg et al., Bio/Technologv 11:905, 1993.
Development of methylotrophic yeasts as hosts for use in recombinant production systems has been slow. due in part to a lack of suitable materials promoters, selectable markers, and mutant host cells) and methods transformation techniques). The most highly developed methylotrophic host systems utilize Pichia pastoris and Hansenula polymorpha (Faber et al., Curr. Genet. 25:305-310, 1994; Cregg et al.. ibid.: Romanos et al.. ibid.: U.S. Patent No.
4,855,242: U.S. Patent No. 4,857,467; U.S. Patent No. 4,879.231; and U.S. Patent No. 4,929,555).
There remains a need in the art for methods of transforming additional species of methylotrophic yeasts and for using the transformed cells to produce polypeptides of economic importance, including industrial enzymes and pharmaceutical proteins. The present invention provides compositions and methods useful in these processes as well as other, related advantages.
Summary of the Invention The present invention provides methods for preparing Pichia methanolica cells having an auxotrophic mutation. The methods comprise the steps of exposing P. methanolica cells to mutagenizing conditions; culturing the cells from step in a rich medium to allow mutations to become established and replicated in at least a portion of the cells: culturing the cells from step in a culture medium deficient in assimilable nitrogen to deplete cellular nitrogen stores: culturing the cells from step in a defined culture medium comprising an inorganic nitrogen source and an amount of nystatin sufficient to kill growing P. methanolica cells to select WO 98/02536 PCT/US97/12582 for cells having a deficiency in a nutritional gene: and culturing the selected cells from step (d) in a rich culture medium. Within one embodiment of the invention, the selected cells from step (e) are replica plated to a defined medium and cultured to confirm the presence of an auxotrophic mutation. Within another embodiment, the selected cells are auxotrophic for adenine. Within a related embodiment, the selected cells are deficient in carboxylase. Within additional embodiments the mutagenizing conditions comprise exposure to ultraviolet light or exposure to a chemical mutagen. Within a further embodiment, the inorganic nitrogen source comprises ammonium ions.
These and other aspects of the invention will become evident upon reference to the following detailed description and the attached drawings.
Brief Description of the Drawings Fig. 1 illustrates the effects of field strength and pulse duration on electroporation efficiency of P. methanolica.
Fig. 2 is a schematic diagram of a recombination event between plasmid pCZR140 and P. methanolica genomic DNA.
Fig. 3 is a schematic diagram of a recombination event between plasmid pCZR137 and P. methanolica genomic DNA.
Detailed Description of the Invention Prior to setting forth the invention in more detail, it will be useful to define certain terms used herein: A "DNA construct" is a DNA molecule, either single- or double-stranded, that has been modified through human intervention to contain segments of DNA combined and juxtaposed in an arrangement not existing in nature.
"Early log phase growth" is that phase of cellular growth in culture when the cell concentration is from 2 x 10 6 cells/ml to 8 x 10 6 cells/ml.
"Heterologous DNA" refers to a DNA molecule, or a population of DNA molecules, that does not exist naturally within a given host cell. DNA molecules heterologous to a particular host cell may contain DNA derived from the host cell species so long as that host DNA is combined with non-host DNA. For example, a DNA molecule containing a non-host DNA segment encoding a polypeptide operably linked to a host DNA segment comprising a transcription promoter is considered to be a heterologous DNA molecule.
A "higher eukaryotic" organism is a multicellular eukarvotic organism. The term encompasses both plants and animals.
"Integrative transformants" are cells into which has been introduced heterologous DNA. wherein the heterologous DNA has become integrated into the genomic DNA of the cells.
"Linear DNA" denotes DNA molecules having free 5' and 3' ends. that is noncircular DNA molecules. Linear DNA can be prepared from closed circular DNA molecules, such as plasmids. by enzymatic digestion or physical disruption.
1 WO 98/02536 PCT/US97/12582 The term "operably linked" indicates that DNA segments are arranged so that they function in concert for their intended purposes, transcription initiates in the promoter and proceeds through the coding segment to the terminator.
The term "promoter" is used herein for its art-recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes. Sequence elements within promoters that function in the initiation of transcription are often characterized by consensus nucleotide sequences. These promoter elements include RNA polymerase binding sites; TATA sequences; CAAT sequences; differentiation-specific elements (DSEs; McGehee et al., Mol. Endocrinol. 7:551-560, 1993); cyclic AMP response elements (CREs); serum response elements (SREs; Treisman, Seminars in Cancer Biol. 1:47-58, 1990); glucocorticoid response elements (GREs); and binding sites for other transcription factors, such as CRE/ATF (O'Reilly et al., J. Biol. Chem. 267:19938-19943, 1992), AP2 (Ye et al.. J. Biol. Chem. 269:25728- 25734. 1994). SP1. cAMP response element binding protein (CREB: Loeken, Gene Expr. 3:253- 264, 1993) and octamer factors. See. in general. Watson et al.. eds., Molecular Biolovg of the Gene.
4th ed., The Benjamin/Cummings Publishing Company, Inc.. Menlo Park. CA. 1987: and Lemaigre and Rousseau, Biochem. J. 303:1-14, 1994.
A "repressing carbon source" is a metabolizable, carbon-containing compound that, when not limited, suppresses the expression in an organism of genes required for the catablism of other carbon sources. By "limited" is meant that the carbon source is unavailable or becomes available at such a rate that it is immediately consumed and therefore the prevailing concentration of that carbon source in an organism's environment is effectively zero. Repressing carbon sources that can be used within the present invention include hexoses and ethanol. Glucose is particularly preferred.
"Rich" culture media are those culture media that are based on complex sources of nutrients, typically cell or tissue extracts or protein hydrolysates. Rich media will vary in composition from batch to batch due to variations in the composition of the nutrient sources.
As noted above, the present invention provides methods for preparing Pichia methanolica cells having an auxotrophic mutation. Auxotrophic mutants of P. methanolica can be transformed with both homologous DNA (DNA from the host species) and heterologous DNA, and the resulting transformants can be used within a large number of diverse biological applications.
The mutant cells of the present invention are particularly well suited for transformation with heterologous DNA. which transformed cells can be used for the production of polypeptides and proteins, including polypeptides and proteins of higher organisms, including humans. Auxotrophic P. methanolica cells can be transformed with other DNA molecules, including DNA libraries and synthetic DNA molecules. The invention thus provides host cells that can be used to express genetically diverse libraries to produce products that are screened for novel biological activities, can be engineered for use as targets for the screening of compound libraries, and can be genetically modified to enhance their utility within other processes.
Cells to be transformed with heterologous DNA will commonly have a mutation that can be complemented by a gene (a "selectable marker") on the heterologous DNA molecule. This WO 98/02536 PCT/US97/12582 4 selectable marker allows the transformed cells to grow under conditions in which untransformed cells cannot multiply ("selective conditions"). The general principles of selection are well known in the art. Commonly used selectable markers are genes that encode enzymes required for the synthesis of amino acids or nucleotides. Cells having mutations in these genes (auxotrophic mutants) cannot grow in media lacking the specific amino acid or nucleotide unless the mutation is complemented by the selectable marker. Use of such "selective" culture media ensures the stable maintenance of the heterologous DNA within the host cell. A preferred selectable marker of this type for use in Pichia methanolica is a P. methanolica ADE2 gene. which encodes phosphoribosylcarboxylase (AIRC; EC 4.1.1.21). The ADE2 gene. when transformed into an ade2 host cell, allows the cell to grow in the absence of adenine. The coding strand of a representative P. methanolica ADE2 gene sequence is shown in SEQ ID NO:1. The sequence illustrated includes 1006 nucleotides of 5' non-coding sequence and 442 nucleotides of 3' noncoding sequence, with the initiation ATG codon at nucleotides 1007-1009. Within a preferred embodiment of the invention, a DNA segment comprising nucleotides 407-2851 is used as a selectable marker, although longer or shorter segments could be used as long as the coding portion is operably linked to promoter and terminator sequences. Those skilled in the art will recognize that this and other sequences provided herein represent single alleles of the respective genes, and that allelic variation is expected to exist. Any functional ADE2 allele can be used within the .present invention. Other nutritional markers that can be used within the present invention include the P.
methanolica ADE.1 HIS3, and LEU2 genes, which allow for selection in the absence of adenine, histidine. and leucine. respectively. Heterologous genes. such as genes from other fungi. can also be used as selectable markers. For large-scale, industrial processes where it is desirable to minimize the use of methanol, it is preferred to use host cells in which both methanol utilization genes (AUGI and AUG2) are deleted. For production of secreted proteins, host cells deficient in vacuolar protease genes (PEP4 and PRB1) are preferred. Gene-deficient mutants can be prepared by known methods, such as site-directed mutagenesis. P. methanolica genes can be cloned on the basis of homology with their counterpart Saccharomyces cerevisiae genes. The ADE2 gene disclosed herein was given its designation on the basis of such homology.
Strains of Pichia methanolica are available from the American Type Culture Collection (Rockville. MD) and other repositories, and can be used as starting materials within the present invention. To prepare auxotrophic mutants of P. methanolica, cells are first exposed to mutagenizing conditions, i.e. environmental conditions that cause genetic mutations in the cells.
Methods for mutagenizing cells are well known in the art and include chemical treatment, exposure to ultraviolet light, exposure to x-rays, and retroviral insertional mutagenesis. Chemical mutagens include ethylmethane sulfonate (EMS). N-methyl-AN-nitro-N-nitrosoguanidine. 2-methoxv-6chloro-9-[3-(ethyl-2-chloroethyl)aminopropylamino]acridine2HC, 5-bromouracil. acridine. and aflatoxin. See Lawrence. Methods Enzmol. 194:273-281. 1991. The proportion of mutagenized cells obtained is a function of the strength or amount of mutagenizing agent to which the cells are exposed. A low level of mutagen produces a small proportion of mutant cells. Higher levels of mutagen produce a higher proportion of mutant cells, but also kill more cells. It is therefore necessary to balance mutagenesis with killing so that a reasonable number of mutant cells is WO 98/02536 WO 98/02536 PCT/US97/12582 obtained. Balancing is generally done empirically by exposing cells to different conditions to establish a killing curve. In general, the cells are exposed to mutagenizing conditions and cultured for one day. after which they are tested for viability according to standard assay methods. Within the present invention, it is preferred to use a level of mutagenesis that results in 20-50% mortality.
although one skilled in the art will recognize that this value can be adjusted as necessary, for example if working with a very large number of cells.
Mutagenized cells are then cultured in a rich medium to allow mutations to become established and replicated in at least a portion of the cell population. This step allows cells in which the genome has been altered to replicate the mutation and pass it on to their progeny, thereby establishing the mutation within the population.
The cells are then transferred to a culture medium deficient in assimilable nitrogen so that cellular nitrogen stores are depleted. By "deficient in assimilable nitrogen" it is meant that the medium lacks an amount of nitrogen sufficient to support growth of the cells. Depletion of cellular nitrogen stores will generally require about 12 to 24 hours of incubation, with 16 hours being sufficient under common conditions. Following depletion of nitrogen stores, the cells are cultured in a defined culture medium comprising an inorganic nitrogen source and an amount of an antifungal antibiotic sufficient to kill growing P. methanolica cells. A preferred antibiotic is nystatin (mycostatin). Preferred inorganic nitrogen sources are those comprising ammonium ions, such as ammonium sulfate. In general, the medium will contain 10-200 mM ammonium, preferably about 60 mM ammonium. Nystatin is included at a concentration of 0.1 to 100 mg/1, preferably 0.5 to mg/L, more preferably about 2 mg/L (10 units/L). Treatment with nystatin is carried out for ten minutes to six hours, preferably about 1 hour. Those skilled in the art will recognize that the actual antibiotic concentration and exposure time required to kill prototrophic cells can be readily determined empirically, and certain adjustments may be necessary to compensate for variations in specific activity between individual batches of antibiotic. By depleting cellular nitrogen stores and then culturing the cells in a defined medium containing an inorganic nitrogen source and antibiotic.
cells that are auxotrophic for amino acid or nucleotide biosynthesis remain alive because they cannot grow in the defined medium. Growing cells are killed by the antibiotic. Following the antibiotic treatment, the cells are transferred to a rich culture medium.
Auxotrophic mutations are confirmed and characterized by determining the nutrient requirements of the treated cells. Replica plating is commonly used for this determination. Cells are plated on both rich medium and media lacking specific nutrients. Cells that do not grow on particularly plates are auxotrophic for the missing nutrient. Complementation analysis can be used for further characterization.
Heteroiogous DNA can be introduced into P. methanolica cells by any of several known methods, including lithium transformation (Hiep et al. Yeast 9:1189-1197. 1993: Tarutina and Tolstorukov, Abst. of the 15th International Specialized Symposium on Yeasts. Riga (USSR).
1991. 137: Ito et al.. J. Bacteriol. 153:163. 1983: Bogdanova et al.. Yeast 11:343. 1995). spheroplast transformation (Beggs, Nature 275:104, 1978; Hinnen et al., Proc. Natl. Acad. Sci. USA 75:1929.
1978; Cregg et al., Mol. Cell. Biol. 5:3376, 1985), freeze-thaw polyethylene glycol transformation (Pichia Expression Kit Instruction Manual, Invitrogen Corp.. San Diego, CA. Cat. No. K1710-01).
WO 98/02536 PCT/US97/12582 6 or electroporation, the latter method being preferred. Electroporation is the process of using a pulsed electric field to transiently permeabilize cell membranes, allowing macromolecules. such as DNA, to pass into cells. Electroporation has been described for use with mammalian Neumann et al., EMBO J. 1:841-845, 1982) and fungal Meilhoc et al.. Bio/Technologv 8:223- 227. 1990) host cells. However, the actual mechanism by which DNA is transferred into the cells is not well understood. For transformation of P. methanolica. it has been found that electroporation is surprisingly efficient when the cells are exposed to an exponentially decaying, pulsed electric field having a field strength of from 2.5 to 4.5 kV/cm and a time constant of from 1 to milliseconds. The time constant is defined as the time required for the initial peak voltage V 0 to drop to a value of Vo/e. The time constant can be calculated as the product of the total resistance and capacitance of the pulse circuit, T R x C. Typically, resistance and capacitance are either preset or may be selected by the user, depending on the electroporation equipment selected. In any event, the equipment is configured in accordance with the manufacturer's instructions to provide field strength and decay parameters as disclosed above. Electroporation equipment is available from commercial suppliers BioRad Laboratories. Hercules. CA).
DNA molecules for use in transforming P. methanolica will commonly be prepared as double-stranded, circular plasmids, which are preferably linearized prior to transformation. For polypeptide or protein production, the DNA molecules will include, in addition to the selectable marker disclosed above, an expression casette comprising a transcription promoter, a DNA segment a cDNA) encoding the polypeptide or protein of interest, and a transcription terminator. These elements are operably linked to provide for transcription of the DNA segment of interest. It is preferred that the promoter and terminator be that of a P. methanolica gene. Useful promoters include those from constitutive and methanol-inducible promoters. Promoter sequences are generally contained within 1.5 kb upstream of the coding sequence of a gene. often within 1 kb or less. In general, regulated promoters are larger than constitutive promoters due the presence of regulatory elements. Methanol-inducible promoters, which include both positive and negative regulatory elements, may extend more than 1 kb upstream from the initiation ATG. Promoters are identified by function and can be cloned according to known methods.
A particularly preferred methanol-inducible promoter is that of a P. methanolica alcohol utilization gene. A representative coding strand sequence of one such gene. AUG]. is shown in SEQ ID NO:2. Within SEQ ID NO:2, the initiation ATG codon is at nucleotides 1355- 1357. Nucleotides 1-23 of SEQ ID NO:2 are non-AUG1 polylinker sequence. It is particularly preferred to utilize as a promoter a segment comprising nucleotides 24-1354 of SEQ ID NO:2, although additional upstream sequence can be included. P. methanolica contains a second alcohol utilization gene. A UG2, the promoter of which can be used within the present invention. A partial DNA sequence of one AUG2 clone is shown in SEQ ID NO:9. AUG2 promoter segments used within the present invention will generally comprise nucleotides 91-169 of SEQ ID NO:9. although small truncations at the 3' end would not be expected to negate promoter function. Other useful promoters include those of the dihydroxyacetone synthase (DHAS), formate dehydrogenase (FMD), and catalase (CAT) genes. Genes encoding these enzymes from other species have been described.
and their sequences are available Janowicz et al., Nuc. Acids Res. 13:2043. 1985: Hollenberg WO 98/02536 PCT/US97/12582 7 and Janowicz. EPO publication 0 299 108; Didion and Roggenkamp, FEBS Lett. 303:113, 1992).
Genes encoding these proteins can be cloned by using the known sequences as probes, or by aligning known sequences, designing primers based on the alignment, and amplifying P.
methanolica DNA by the polymerase chain reaction (PCR).
Constitutive promoters are those that are not activated or inactivated by environmental conditions; they are always transcriptionally active. Preferred constitutive promoters for use within the present invention include those from glyceraldehyde-3-phosphate dehydrogenase, triose phosphate isomerase, and phosphoglycerate kinase genes of P. methanolica. These genes can be cloned by complementation in a host cell, such as a Saccharomyces cerevisiae cell, having a mutation in the counterpart gene. Mutants of this type are well known in the art. See. for example, Kawasaki and Fraenkel, Biochem. Biophvs. Res. Comm. 108:1107-1112, 1982; McKnight et al., Cell 46:143-147, 1986; Aguilera and Zimmermann, Mol. Gen. Genet. 202:83-89. 1986.
The DNA molecules will further include a selectable marker to allow for identification, selection. and maintenance of transformants. The DNA molecules may further contain additional elements, such an origin of replication and a selectable marker that allow amplification and maintenance of the DNA in an alternate host E. coli). To facilitate integration of the DNA into the host chromosome, it is preferred to have the entire expression segment, comprising the promoter--gene of interest--terminator plus selectable marker, flanked at both ends by host DNA sequences. This is conveniently accomplished by including 3' untranslated DNA sequence at the downstream end of the expression segment and relying on the promoter sequence at the 5' end. When using linear DNA, the expression segment will be flanked by cleavage sites to allow for linearization of the molecule and separation of the expression segment from other sequences a bacterial origin of replication and selectable marker). Preferred such cleavage sites are those that are recognized by restriction endonucleases that cut infrequently within a DNA sequence. such as those that recognize 8-base target sequences Not I).
Proteins that can be produced in P. methanolica include proteins of industrial and pharmaceutical interest. Such proteins include higher eukaryotic proteins from plants and animals, particularly vertebrate animals such as mammals, although certain proteins from microorganisms are also of great value. Proteins that can be prepared using methods of the present invention include enzymes such as lipases, cellulases, and proteases; enzyme inhibitors, including protease inhibitors; growth factors such as platelet derived growth factor, fibroblast growth factors, and epidermal growth factor; cytokines such as erythropoietin and thrombopoietin; and hormones such as insulin. leptin. and glucagon For production of polypeptides, P. methanolica cells are cultured in a medium comprising adequate sources of carbon, nitrogen and trace nutrients at a temperature of about to 35 0 C. Liquid cultures are provided with sufficient aeration by conventional means, such as shaking of small flasks or sparging of fermentors. A preferred culture medium is YEPD (Table 1).
The cells may be passaged by dilution into fresh culture medium or stored for short periods on plates under refrigeration. For long-term storage, the cells are preferably kept in a 50% glycerol solution at -70 0
C.
Table 1 WO 98/02536 PCTIUS97/12582 8
YEPD
2% D-giucose 2%Im_ oT Peptone (Difco Laboratories. Detroit. MI) I BactOTM yeast extract (Difco Laboratories) 0.004% adenine 0.006% L-Ieucine WO 98/02536 PCT/US97/12582 9 Table 1. continued ADE D 0.056% -Ade -Trp -Thr powder 0.67% yeast nitrogen base without amino acids 2% D-glucose 200X tryptophan, threonine solution ADE DS 0.056% -Ade -Trp -Thr powder 0.67% yeast nitrogen base without amino acids 2% D-glucose 200X tryptophan, threonine solution 18.22% D-sorbitol LEU D 0.052% -Leu -Trp -Thr powder 0.67% yeast nitrogen base without amino acids 2% D-glucose 200X tryptophan, threonine solution
HISD
0.052% -His -Trp -Thr powder 0.67% yeast nitrogen base without amino acids 2% D-glucose 200X tryptophan, threonine solution URA D 0.056% -Ura -Trp -Thr powder 0.67% yeast nitrogen base without amino acids 2% D-glucose 200X tryptophan, threonine solution URA DS 0.056% -Ura -Trp -Thr powder 0.67% yeast nitrogen base without amino acids 2% D-glucose 200X tryptophan, threonine solution 18.22% D-sorbitol i 1 WO 98/02536 PCT/US97/12582 Table 1. continued -Leu -Trp -Thr powder powder made by combining 4.0 g adenine. 3.0 g arginine. 5.0 g aspartic acid. 2.0 g histidine.
g isoleucine. 4.0 g lysine. 2.0 g methionine, 6.0 g phenylalanine. 5.0 g serine. 5.0 g tyrosine. 4.0 g uracil. and 6.0 g valine (all L- amino acids) -His -Trp -Thr powder powder made by combining 4.0 g adenine. 3.0 g arginine. 5.0 g aspartic acid. 6.0 g isoleucine, 8.0 g leucine, 4.0 g lysine. 2.0 g methionine. 6.0 g phenylalanine. 5.0 g serine.
g tyrosine. 4.0 g uracil, and 6.0 g valine (all L- amino acids) -Ura -Trp -Thr powder powder made by combining 4.0 g adenine, 3.0 g arginine, 5.0 g aspartic acid. 2.0 g histidine.
g isoleucine. 8.0 g leucine, 4.0 g lysine, 2.0 g methionine. 6.0 g phenylalanine. 5.0 g serine, 5.0 g tyrosine. and 6.0 g valine (all L- amino acids) -Ade -Trp -Thr powder powder made by combining 3.0 g arginine, 5.0 g aspartic acid. 2.0 g histidine. 6.0 g isoleucine, 8.0 g leucine. 4.0 g lysine. 2.0 g methionine. 6.0 g phenylalanine. 5.0 g serine.
g tyrosine. 4.0 g uracil, and 6.0 g valine (all L- amino acids) 200X trvptophan, threonine solution L-threonine. 0.8% L-tryptophan in H 2 0 For plates. add 1.8% BactoTM agar (Difco Laboratories) Electroporation of P. methanolica is preferably carried out on cells in early log phase growth. Cells are streaked to single colonies on solid media, preferably solid YEPD. After about 2 days of growth at 30 0 C. single colonies from a fresh plate are used to inoculate the desired volume of rich culture media YEPD) to a cell density of about 5 10 x 105 cells/ml. Cells are incubated at about 25 35 0 C, preferably 30 0 C, with vigorous shaking, until they are in early log phase. The cells are then harvested, such as by centrifugation at 3000 x g for 2-3 minutes, and resuspended. Cells are made electrocompetent by reducing disulfide bonds in the cell walls.
equilibrating them in an ionic solution that is compatible with the electroporation conditions, and chilling them. Cells are typically made electrocompetent by incubating them in a buffered solution at pH 6-8 containing a reducing agent, such as dithiothreitol (DTT) or P-mercaptoethanol (BME). to reduce cell wall proteins to facilitate subsequent uptake of DNA. A preferred incubation buffer in this regard is a fresh solution of 50 mM potassium phosphate buffer, pH 7.5, containing 25 mM DTT. The cells are incubated in this buffer (typically using one-fifth the original culture volume) at about 30°C for about 5 to 30 minutes, preferably about 15 minutes. The cells are then harvested and washed in a suitable electroporation buffer, which is used ice-cold. Suitable buffers in this regard include pH 6-8 solutions containing a weak buffer, divalent cations Mg Ca^ and an osmotic stabilizer a sugar). After washing, the cells are resuspended in a small volume of the buffer, at which time they are electrocompetent and can be used directly or aliquoned and stored frozen (preferably at -70 0 A preferred electroporation buffer is STM (270 mM sucrose, 10 mM Tris, pH 7.5. 1 mM MgCl2). Within a preferred protocol. the cells are subjected to two washes, first
I
WO 98/02536 PCT/US97/12582 11 in the original culture volume of ice-cold buffer. then in one-half the original volume. Following the second wash, the cells are harvested and resuspended, typically using about 3-5 ml of buffer for an original culture volume of 200 ml.
Electroporation is carried out using a small volume of electrocompetent cells (typically about 100 tl) and up to one-tenth volume of linear DNA molecules. For example, 0.1 ml of cell suspension in a buffer not exceeding 50 mM in ionic strength is combined with 0.1-10 jig of DNA (vol. 10 ul). This mixture is placed in an ice-cold electroporation cuvette and subjected to a pulsed electric field of from 2.5 to 4.5 kV/cm, preferably about 3.75 kV/cm, and a time constant of from 1 to 40 milliseconds, preferably 10-30 milliseconds. more preferably 15-25 milliseconds, most preferably about 20 milliseconds, with exponential decay. The actual equipment settings used to achieve the desired pulse parameters will be determined by the equipment used. When using a BioRad (Hercules, CA) Gene PulserTM electroporator with a 2 mm electroporation cuvette, resistance is set at 600 ohms or greater, preferably "infinite" resistance, and capacitance is set at gtF to obtain the desired field characteristics. After being pulsed, the cells are diluted approximately 1 OX into 1 ml of YEPD broth and incubated at 30 0 C for one hour.
The cells are then harvested and plated on selective media. Within a preferred embodiment, the cells are washed once with a small volume (equal to the diluted volume of the electroporated cells) of 1X yeast nitrogen base (6.7 g/L yeast nitrogen base without amino acids; Difco Laboratories, Detroit, MI), and plated on minimal selective media. Cells having an ade2 mutation that have been transformed with an ADE2 selectable marker can be plated on a minimal medium that lacks adenine. such as ADE D (Table 1) or ADE DS (Table In a typical procedure, 250 pl aliqouts of cells are plated on 4 separate ADE D or ADE DS plates to select for Ade cells.
P. methanolica recognizes certain infrequently occuring sequences, termed autonomously replicating sequences (ARS). as origins of DNA replication, and these sequences may fortuitously occur within a DNA molecule used for transformation, allowing the transforming DNA to be maintained extrachromosomally. However, integrative transformants are generally preferred for use in protein production systems. Integrative transformants have a profound growth advantage over ARS transformants on selective media containing sorbitol as a carbon source, thereby providing a method for selecting integrative transformants from among a population of transformed cells. ARS sequences have been found to exist in the ADE2 gene and, possibly, the AUGI gene of P. methanolica. ade2 host cells of Pichia methanolica transformed with an ADE2 gene can thus become Ade by at least two different modes. The ARS within the ADE2 gene allows unstable extrachromosomal maintenance of the transforming DNA (Hiep et al., Yeast 9:1189-1197. 1993). Colonies of such transformants are characterized by slower growth rates and pink color due to prolific generation of progeny that are Ade-. Transforming DNA can also integrate into the host genome, giving rise to stable transformants that grow rapidly. are white, and that fail to give rise to detectable numbers of Ade- progeny. ADE D plates allow the most rapid growth of transformed cells. and unstable and stable transformants grow at roughly the same rates.
After 3-5 days of incubation on ADE D plates at 30 0 C stable transformant colonies are white and roughly twice the size of unstable, pink transformants. ADE DS plates are more selective for stable transformants, which form large (z5 mm) colonies in 5-7 days, while unstable (ARS-maintained) WO 98/02536 PCT/US97/12582 12 colonies are much smaller mm). The more selective ADE DS media is therefore preferred for the identification and selection of stable transformants. For some applications, such as the screening of genetically diverse libraries for rare combinations of genetic elements, it is sometimes desirable to screen large numbers of unstable transformants, which have been observed to outnumber stable transformants by a factor of roughly 100. In such cases, those skilled in the art will recognize the utility of plating transformant cells on less selective media, such as ADE D.
Integrative transformants are preferred for use in protein production processes. Such cells can be propagated without continuous selective pressure because DNA is rarely lost from the genome. Integration of DNA into the host chromosome can be confirmed by Southern blot analysis. Briefly, transformed and untransformed host DNA is digested with restriction endonucleases, separated by electrophoresis, blotted to a support membrane, and probed with appropriate host DNA segments. Differences in the patterns of fragments seen in untransformed and transformed cells are indicative of integrative transformation. Restriction enzymes and probes can be selected to identify transforming DNA segments promoter, terminator, heterologous DNA, and selectable marker sequences) from among the genomic fragments.
Differences in expression levels of heterologous proteins can result from such factors as the site of integration and copy number of the expression cassette and differences in promoter activity among individual isolates. It is therefore advantageous to screen a number of isolates for expression level prior to selecting a production strain. A variety of suitable screening methods are available. For example, transformant colonies are grown on plates that are overlayed with membranes nitrocellulose) that bind protein. Proteins are released from the cells by secretion or following lysis. and bind to the membrane. Bound protein can then be assayed using known methods, including immunoassays. More accurate analysis of expression levels can be obtained by culturing cells in liquid media and analyzing conditioned media or cell lysates. as appropriate.
Methods for concentrating and purifying proteins from media and lysates will be determined in part by the protein of interest. Such methods are readily selected and practiced by the skilled practitioner.
For small-scale protein production plate or shake flask production), P.
methanolica transformants that carry an expression cassette comprising a methanol-regulated promoter (such as the AUG1 promoter) are grown in the presence of methanol and the absence of interfering amounts of other carbon sources glucose). For small-scale experiments, including preliminary screening of expression levels, transformants may be grown at 30 0 C on solid media containing, for example. 20 g/L Bacto-agar (Difco), 6.7 g/L yeast nitrogen base without amino acids (Difco). 10 g/L methanol, 0.4 g/L biotin. and 0.56 g/L of -Ade -Thr -Trp powder. Because methanol is a volatile carbon source it is readily lost on prolonged incubation. A continuous supply of methanol can be provided by placing a solution of 50% methanol in water in the lids of inverted plates. whereby the methanol is transferred to the growing cells by evaporative transfer. In general.
not more than 1 mL of methanol is used per 100-mm plate. Slightly larger scale experiments can be carried out using cultures grown in shake flasks. In a typical procedure, cells are cultivated for two days on minimal methanol plates as disclosed above at 30 0 C. then colonies are used to inoculate a small volume of minimal methanol media (6.7 g/L yeast nitrogen base without amino acids. 10 g/L 1 WO 98/02536 PCT/US97/12582 13 methanol. 0.4 gpg/L biotin) at a cell density of about 1 x 106 cells/ml. Cells are grown at Cells growing on methanol have a high oxygen requirement, necessitating vigorous shaking during cultivation. Methanol is replenished daily (typically 1/100 volume of 50% methanol per day).
For production scale culturing, fresh cultures of high producer clones are prepared in shake flasks. The resulting cultures are then used to inoculate culture medium in a fermenter.
Typically, a 500 ml culture in YEPD grown at 30°C for 1-2 days with vigorous agititation is used to inoculate a 5-liter fermenter. The cells are grown in a suitable medium containing salts, glucose, biotin, and trace elements at 28 0 C, pH 5.0, and >30% dissolved 02. After the initial charge of glucose is consumed (as indicated by a decrease in oxygen consumption), a glucose/methanol feed is delivered into the vessel to induce production of the protein of interest. Because large-scale fermentation is carried out under conditions of limiting carbon, the presence of glucose in the feed does not repress the methanol-inducible promoter. The use of glucose in combination with methanol under glucose-limited conditions produces rapid growth, efficient conversion of carbon to biomass and rapid changes in physiological growth states, while still providing full induction of methanol-inducible gene promoters. In a typical fermentation run, a cell density of from about 80 to about 400 grams of wet cell paste per liter is obtained. "Wet cell paste" refers to the mass of cells obtained by harvesting the cells from the fermentor, typically by centrifugation of the culture.
The invention is further illustrated by the following non-limiting examples.
Examples Example 1 P. methanolica cells (strain CBS6515 from American Type Culture Collection, Rockville. MD) were mutagenized by UV exposure. A killing curve was first generated by plating cells onto several plates at approximately 200-250 cells/plate. The plates were then exposed to UV radiation using a G8T5 germicidal lamp (Sylvania) suspended 25 cm from the surfaces of the plates for periods of time as shown in Table 2. The plates were then protected from visible light sources and incubated at 30 0 C for two days.
r WO 98/02536 PCT/US97/12582 14 Table 2 Viable Cells Time Plate 1 Plate 2 Average 0 sec. 225 229 227 1 sec. 200 247 223 2 sec. 176 185 181 4 sec. 149 86 118 8 sec. 20 7 14 16 sec. 0 2 1 Large-scale mutagenesis was then carried out using a 2-second UV exposure to provide about 20% killing. Cells were plated at approximately 104 cells/plate onto eight YEPD plates that were supplemented with 100 mg/L each of uracil. adenine. and leucine. which were added to supplement the growth of potential auxotrophs having the cognate deficiencies. Following UV exposure the plates were wrapped in foil and incubated overnight at 30 0 C. The following day the colonies on the plates (-105 total) were resuspended in water and washed once with water. An amount of cell suspension sufficient to give an OD 60 0 of 0.1 0.2 was used to inoculate 500 ml of minimal broth made with yeast nitrogen base without amino acids or ammonia, supplemented with 1% glucose and 400 pg/L biotin. The culture was placed in a 2.8 L baffled Bell flask and shaken vigorously overnight at 30 0 C. The following day the cells had reached an OD 60 0 of -1.0 The cells were pelleted and resuspended in 500 ml of minimal broth supplemented with 5 g/L ammonium sulfate. The cell suspension was placed in a 2.8 L baffled Bell flask and shaken vigorously at 30 0 C for 6 hours. 50 ml of the culture was set aside in a 250-ml flask as a control, and to the remainder of the culture was added 1 mg nystatin (Sigma Chemical Co.. St. Louis, MO) to select for auxotrophic mutants (Snow, Nature 211:206-207. 1966). The cultures were incubated with shaking for an additional hour. The control and nystatin-treated cells were then harvested by centrifugation and washed with water three times. The washed cells were resuspended to an OD 6 0 0 of 1.0 in 50% glycerol and frozen. Titering of nystatin-treated cells versus the control cells for colony forming units revealed that nystatin enrichment had decreased the number of viable cells by a factor of 104.
10-2 dilutions of nystatin-treated cells were plated on 15 YEPD plates. Colonies were replica-plated onto minimal plates agar, 1 x YNB. 2% glucose. 400 utg/L biotin). The frequency of auxotrophs was about 2 Approximately 180 auxotrophic colonies were picked to YEPD Ade. Leu, Ura plates and replica-plated to various dropout plates. All of the auxotrophs were Ade-. Of these. 30 were noticably pink on dropout plates (LEU D. HIS D. etc.: see Table 1).
Of the 30 pink mutants, 21 were chosen for further study: the remainder were either leaky for growth on ADE D plates or contaminated with wild-type cells.
The Ade- mutants were then subjected to complementation analysis and phenotypic testing. To determine the number of loci defined by the mutants, all 21 mutants were mated to a single pink. Ade- tester strain (strain Mating was carried out by mixing cell suspensions
(OD
60 0 1) and plating the mixtures in 10 ul aliquots on YEPD plates. The cells were then WO 98/02536 PCT/US97/12582 replicated to SPOR media Na acetate, 1% KC1, 1% glucose, 1% agar) and incubated overnight at 30 0 C. The cells were then replica-plated to ADE D plates for scoring of phenotype.
As shown in Table 3. some combinations of mutants failed to give Ade+ colonies (possibly defining the same genetic locus as in strain while others gave rise to numerous Adel colonies (possibly defining a separate genetic locus). Because mutant #3 gave Ade colonies when mated to #2.
complementation testing was repeated with mutant If the group of mutants defined two genetic loci, then all mutants that failed to give Ade+ colonies when mated to strain #2 should give Ade+ colonies when mated to Results of the crosses are shown in Table 3.
Table 3 Mutant x Mutant #2 x Mutant #3 #1 #3 #18 #24 #28 #2 #8 #9 #11 #17- #19 tinued #22- #27 #4 #12 #16 Table 3. con As shown in Table 3. most mutants fell into one of two groups, consistent with the idea that there are two adenine biosynthetic genes that. when missing, result in pink colonies on limiting adenine media. Three colonies #12. and #16) may either define a third locus or exhibit intragenic complementation. Two intensely pigmented mutants from each of the two complementation groups and #10: #6 and #11) were selected for further characterization.
Additional analysis indicated that Ade- was the only auxotrophy present in these strains.
WO 98/02536 WO 98/02536 PCT/US97/12582 16 A P. methanolica clone bank was constructed in the vector pRS426. a shuttle vector comprising 2 and S. cerevisiae URA3 sequences. allowing it to be propagated in S. cerevisiae.
Genomic DNA was prepared from strain CBS6515 according to standard procedures. Briefly, cells were cultured overnight in rich media, spheroplasted with zymolyase. and lysed with SDS. DNA was precipitated from the lysate with ethanol and extracted with a phenol/chloroform mixture, then precipitated with ammonium acetate and ethanol. Gel electrophoresis of the DNA preparation showed the presence of intact, high molecular weight DNA and appreciable quantities of RNA. The DNA was partially digested with Sau 3A by incubating the DNA in the presence of a dilution series of the enzyme. Samples of the digests were analyzed by electrophoresis to determine the size distribution of fragments. DNA migrating between 4 and 12 kb was cut from the gel and extracted from the gel slice. The size-fractionated DNA was then ligated to pRS426 that had been digested with Bar HI and treated with alkaline phosphatase. Aliquots of the reaction mixture were electroporated in E. coli MC1061 cells using a BioRad Gene PulserT device as recommended by the manufacturer.
The genomic library was used to transform S. cerevisiae strain HBY21A (ade2 ura3) by electroporation (Becker and Guarente, Methods Enzymol. 194:182-187, 1991). The cells were resuspended in 1.2 M sorbitol, and six 3 0 0-pl aliquots were plated onto ADE D, ADE DS, URA D and URA DS plates (Table Plates were incubated at 30 0 C for 4-5 days. No Adel colonies were recovered on the ADE D or ADE DS plates. Colonies from the URA D and URA DS plates were replica-plated to ADE D plates, and two closely spaced, white colonies were obtained. These colonies were restreaked and confirmed to be Ura+ and Ade t These two strains, designated Adel and Ade6. were streaked onto media containing 5 FOA (5 fluoro orotic acid; Sikorski and Boeke, Methods Enzmol. 194:302-318). Ura- colonies were obtained, which were found to be Ade- upon replica plating. These results indicate that the Ade+ complementing activity is genetically linked to the plasmid-borne URA3 marker. Plasmids obtained from yeast strains Adel and Ade6 appeared to be identical by restriction mapping as described below. These genomic clones were designated pADEI-1 and pADE1-6, respectively.
Total DNA was isolated from the HBY21A transformants Adel and Ade6 and used to transform E. coli strain MC1061 to AmpR. DNA was prepared from 2 AmpR colonies of Adel and 3 AmpR colonies of Ade6. The DNA was digested with Pst I, Sca I, and Pst I Sea I and analyzed by gel electrophoresis. All five isolates produced the same restriction pattern.
PCR primers were designed from the published sequence of the P. methanolica ADE2 gene (also known as ADE:1 Hiep et al.. Yeast 9:1251-1258. 1993). Primer 9080 (SEQ ID NO:3) was designed to prime at bases 406-429 of the ADE2 DNA (SEQ ID NO:1), and primer 9079 (SEQ ID NO:4) was designed to prime at bases 2852-2829. Both primers included tails to introduce Avr II and Spe I sites at each end of the amplified sequence. The predicted size of the resulting PCR fragment was 2450 bp.
PCR was carried out using plasmid DNA from the five putative ADE2 clones as template DNA. The 100 p1 reaction mixtures contained Ix Taq PCR buffer (Boehringer Mannheim.
Indianapolis. IN), 10-100 ng of plasmid DNA. 0.25 mM dNTPs. 100 pmol of each primer, and 1 pl Taq polymerase (Boehringer Mannheim). PCR was run for 30 cycles of 30 seconds at 94°C. i WO 98/02536 PCT/US97/12582 17 seconds at 50°C, and 120 seconds at 72 0 C. Each of the five putative ADE2 genomic clones yielded a PCR product of the expected size (2.4 kb). Restriction mapping of the DNA fragment from one reaction gave the expected size fragments when digested with Bgl II or Sal I.
The positive PCR reactions were pooled and digested with Spe I. Vector pRS426 was digested with Spe I and treated with calf intestinal phosphatase. Four pl of PCR fragment and 1 pl of vector DNA were combined in a 10 pl reaction mix using conventional ligation conditions.
The ligated DNA was analyzed by gel electrophoresis. Spe I digests were analyzed to identify plasmids carrying a subclone of the ADE2 gene within pRS426. The correct plasmid was designated pCZRI 18.
Because the ADE2 gene in pCZR 18 had been amplified by PCR, it was possible that mutations that disabled the functional character of the gene could have been generated. To test for such mutations, subclones with the desired insert were transformed singly into Saccharomyces cerevisiae strain HBY21A. Cells were made electrocompetent and transformed according to standard procedures. Transformants were plated on URA D and ADE D plates. Three phenotypic groups were identified. Clones 1, 2, 11, and 12 gave robust growth of many transformants on ADE D. The transformation frequency was comparable to the frequency of Ura+ transformants. Clones 6, 8, 10, and 14 also gave a high efficiency of transformation to both Ura+ and Ade'. but the Ade+ colonies were somewhat smaller than those in the first group. Clone 3 gave many Ura+ colonies, but no Ade+ colonies, suggesting it carried a non-functional ade2 mutation. Clones 1, 2, 11, and 12 were pooled.
To identify the P. methanolica ade2 complementation group, two representative mutants from each complementation group and #10; #6 and which were selected on the basis of deep red pigmentation when grown on limiting adenine, were transformed with the cloned ADE gene. Two hundred ml cultures of early log phase cells were harvested by centrifugation at 3000 x g for 3 minutes and resuspended in 20 ml of fresh KD buffer (50 mM potassium phosphate buffer, pH 7.5, containing 25 mM DTT). The cells were incubated in this buffer at 30 0 C for minutes. The cells were then harvested and resuspended in 200 ml of ice-cold STM (270 mM sucrose, 10 mM Tris, pH 7.5, 1 mM MgCI 2 The cells were harvested and resuspended in 100 ml of ice-cold STM. The cells were again harvested and resuspended in 3-5 ml of ice-cold STM. 100- .l aliquouts of electrocompetent cells from each culture were then mixed with Not I-digested pADE-1 DNA. The cell/DNA mixture was placed in a 2 mm electroporation cuvette and subjected to a pulsed electric field of 5 kV/cm using a BioRad Gene PulserTM set to 1000Q resistance and capacitance of 25 pF. After being pulsed, the cells were diluted by addition of 1 ml YEPD and incubated at 30 0 C for one hour. The cells were then harvested by gentle centrifugation and resuspended in 400 p1 minimal selective media lacking adenine (ADE The resuspended samples were split into 200-pl aliqouts and plated onto ADE D and ADE DS plates. Plates were incubated at 30°C for 4-5 days. Mutants #6 and #11 gave Ade transformants. No Ade transformants were observed when DNA was omitted, hence the two isolates appeared to define the ade2 complementation group. The ADE2 sequence is shown in SEQ ID NO: 1.
Example 2 i WO 98/02536 PCT/US97/12582 18 The P. methanolica clone bank disclosed in Example 1 was used as a source for cloning the Alcohol Utilization Gene (A UG). The clone bank was stored as independent pools, each representing about 200-250 individual genomic clones. 0.1 pl of "miniprep" DNA from each pool was used as a template in a polymerase chain reaction with PCR primers (8784. SEQ ID 8787, SEQ ID NO:6) that were designed from an alignment of conserved sequences in alcohol oxidase genes from Hansenula polymorpha, Candida boidini, and Pichia pastoris. The amplification reaction was run for 30 cycles of 94 0 C, 30 seconds; 50 0 C, 30 seconds; 72°C, seconds; followed by a 7 minute incubation at 72 0 C. One pool gave a -600 bp band. DNA sequencing of this PCR product revealed that it encoded an amino acid sequence with sequence identity with the Pichia pastoris alcohol oxidase encoded by the AOX1 gene and about sequence identity with the Hansenula polymorpha alcohol oxidase encoded by the MOX1 gene. The sequence of the cloned A UGI gene is shown in SEQ ID NO:2.
Sub-pools of pool #5 were analyzed by PCR using the same primers used in the initial amplification. One positive sub-pool was further broken down to identify a positive colony.
This positive colony was streaked on plates, and DNA was prepared from individual colonies.
Three colonies gave identical patterns after digestion with Cla I.
Restriction mapping of the genomic clone and PCR product revealed that the A UG1 gene lay on a 7.5 kb genomic insert and that sites within the PCR fragment could be uniquely identified within the genomic insert. Because the orientation of the gene within the PCR fragment was known, the latter information provided the approximate location and direction of transcription of the A UG1 gene within the genomic insert. DNA sequencing within this region revealed a gene with very high sequence similarity at the amino acid level to other known alcohol oxidase genes.
Example 3 ade2 mutant P. methanolica cells are transformed by electroporation essentially as disclosed above with an expression vector comprising the AUG1 promoter and terminator, human DNA (Karlsen et al., Proc. Natl. Acad. Sci. USA 88:8337-8341, 1991), and ADE2 selectable marker. Colonies are patched to agar minimal methanol plates (10 to 100 colonies per 100-mm plate) containing 20 g/L Bacto
TM
-agar (Difco), 6.7 g/L yeast nitrogen base without amino acids (Difco), 10 g/L methanol, and 0.4 .g/L biotin. The agar is overlayed with nitrocellulose, and the plates are inverted over lids containing 1 ml of 50% methanol in water and incubated for 3 to days at 30 0 C. The membrane is then transferred to a filter soaked in 0.2 M NaOH, 0.1% SDS, mM dithiothreitol to lyse the adhered cells. After 30 minutes, cell debris is rinsed from the filter with distilled water, and the filter is neutralized by rinsing it for 30 minutes in 0.1 M acetic acid.
The filters are then assayed for adhered protein. Unoccupied binding sites are blocked by rinsing in TTBS-NFM (20 mM Tris pH 7.4. 0.1% Tween 20, 160 mM NaCI, powdered nonfat milk) for 30 minutes at room temperature. The filters are then transferred to a solution containing GAD6 monoclonal antibody (Chang and Gottlieb. J. Neurosci. 8:2123-2130.
1988), diluted 1:1000 in TTBS-NFM. The filters are incubated in the antibody solution with gentle agitation for at least one hour. then washed with TTBS (20 mM Tris pH 7.4, 0.1% Tween 20, 160 mM NaCI) two times for five minutes each. The filters are then incubated in goat anti-mouse WO 98/02536 PCT/US97/12582 19 antibody conjugated to horseradish peroxidase (1 gg/ml in TTBS-NFM) for at least one hour, then washed three times, 5 minutes per wash with TTBS. The filters are then exposed to commercially available chemiluminescence reagents (ECLTM; Amersham Inc., Arlington Heights, IL). Light generated from positive patches is detected on X-ray film.
To more accurately detect the level of GAD 65 expression, candidate clones are cultured in shake flask cultures. Colonies are grown for two days on minimal methanol plates at °C as disclosed above. The colonies are used to inoculate 20 ml of minimal methanol media (6.7 g/L yeast nitrogen base without amino acids, 10 g/L methanol. 0.4 gg/L biotin) at a cell density of 1 x 106 cells/ml. The cultures are grown for 1-2 days at 30 0 C with vigorous shaking. 0.2 ml of methanol is added to each culture daily. Cells are harvested by centrifugation and suspended in icecold lysis buffer (20 mM Tris pH 8.0, 40 mM NaC1, 2 mM PMSF, 1 mM EDTA, 1 gg/ml leupeptin, 1 gg/ml pepstatin, 1 gg/ml aprotinin) at 10 ml final volume per 1 g cell paste. 2.5 ml of the resulting suspension is added to 2.5 ml of 400-600 micron, ice-cold, acid-washed glass beads in a 15-ml vessel, and the mixture is vigorously agitated for one minute, then incubated on ice for 1 minute. The procedure is repeated until the cells have been agitated for a total of five minutes.
Large debris and unbroken cells are removed by centrifugation at 1000 x g for 5 minutes. The clarified lysate is then decanted to a clean container. The cleared lysate is diluted in sample buffer SDS, 8 M urea, 100 mM Tris pH 6.8, 10% glycerol, 2 mM EDTA, 0.01% bromphenol glue) and electrophoresed on a 4-20% acrylamide gradient gel (Novex, San Diego, CA). Proteins are blotted to nitrocellose and detected with GAD6 antibody as disclosed above.
Clones exhibiting the highest levels of methanol-induced expression of foreign protein in shake flask culture are more extensively analyzed under high cell density fermentation conditions. Cells are first cultivated in 0.5 liter of YEPD broth at 30 0 C for 1 2 days with vigorous agitation, then used to inoculate a 5-liter fermentation apparatus BioFlow III; New Brunswick Scientific Co., Inc., Edison, NJ). The fermentation vessel is first charged with mineral salts by the addition of 57.8 g (NH 4 2 S0 4 68 g KH 2
PO
4 30.8 g MgSO 4 .7H 2 0 8.6 g CaSO 4 .2H 2 0 2.0 g NaCI, and 10 ml antifoam (PPG). H 2 0 is added to bring the volume to 2.5 L, and the solution is autoclaved 40 minutes. After cooling, 350 ml of 50% glucose, 250 ml 10 X trace elements (Table 25 ml of 200 gg/ml biotin, and 250 ml cell inoculum are added.
Table 4 X trace elements: FeSO 4 .7H 2 0 100mM 27.8 g/L CuSO 4 -5H 2 0 2mM 0.5 g/L ZnCI 2 8mM 1.09 g/L MnSO 4
-H
2 0 8mM 1.35 g/L CoC12-6H 2 0 2mM 0.48 g/L Na2MoO 4 .2H20 ImM 0.24 g/L
H
3 B0 3 8mM 0.5 g/L KI 0.5mm 0.08 g/L biotin
_I
WO 98/02536 PCT/US97/12582 thiamine 0.5 g/L Add 1-2 mis H2S0 4 per liter to bring compounds into solution.
The fermentation vessel is set to run at 28 0 C, pH 5.0, and >30% dissolved O2. The cells will consume the initial charge of glucose, as indicated by a sharp demand for oxygen during glucose consumption followed by a decrease in oxygen consumption after glucose is exhausted.
After exhaustion of the initial glucose charge, a glucose-methanol feed supplemented with NH4 and trace elements is delivered into the vessel at 0.2% glucose, 0.2% methanol for hours followed by 0.1% glucose, 0.4% methanol for 25 hours. A total of 550 grams of methanol is supplied through one port of the vessel as pure methanol using an initial delivery rate of 12.5 ml/hr and a final rate of 25 ml/hr. Glucose is supplied through a second port using a 700 ml solution containing 175 grams glucose, 250 ml 10X trace elements, and 99 g (NH4) 2
SO
4 Under these conditions the glucose and methanol are simultaneously utilized, with the induction of
GAD
6 5 expression upon commencement of the glucose-methanol feed. Cells from the fermentation vessel are analyzed for GAD 6 5 expression as described above for shake flask cultures.
Cells are removed from the fermentation vessel at certain time intervals and subsequently analyzed. Little GAD 6 5 expression is observed during growth on glucose.
Exhaustion of glucose leads to low level expression of the GAD 6 5 protein; expression is enhanced by the addition of MeOH during feeding of the fermentation culture. The addition of methanol has a clear stimulatory effect of the expresion of human GAD 6 5 driven by the methanol-responsive A UG1promoter.
Example 4 Transformation conditions were investigated to determine the electric field conditions. DNA topology, and DNA concentration that were optimal for efficient transformation of P. methanolica. All experiments used P. methanolica ade2 strain #11. Competent cells were prepared as previously described. Electroporation was carried out using a BioRad Gene PulserTM.
Three field parameters influence transformation efficiency by electroporation: capacitance, field strength, and pulse duration. Field strength is determined by the voltage of the electric pulse, while the pulse duration is determined by the resistance setting of the instrument.
Within this set of experiments, a matrix of field strength settings at various resistances was examined. In all experiments, the highest capacitance setting (25 pF) of the instrument was used.
100 pl aliquots of electrocompetent cells were mixed on ice with 10 pi of DNA that contained approximately 1 pg of the ADE2 plasmid pCZR133 that had been linearized with the restriction enzyme Not I. Cells and DNA were transferred to 2 mm electroporation cuvettes (BTX Corp., San Diego, CA) and electropulsed at field strengths of 0.5 kV (2.5 kV/cm), 0.75 kV (3.75 kV/cm), kV (5.0 kV/cm), 1.25 kV (6.25 kV/cm). and 1.5 kV (7.5 kV/cm). These field strength conditions were examined at various pulse durations. Pulse duration was manipulated by varying the instrument setting resistances to 200 ohms, 600 ohms, or "infinite" ohms. Pulsed cells were suspended in YEPD and incubated at 30°C for one hour, harvested, resuspended, and plated. Three separate sets of experiments were conducted. In each set, electroporation conditions of 0.75 kV WO 98/02536 PCT/US97/12582 21 (3.75 kV/cm) at a resistance of "infinite" ohms was found to give a dramatically higher transformation efficiency than other conditions tested (see Fig. 1).
After the optimal pulse conditions were established, the influence of DNA topology on transformation efficiency was investigated. Electrocompetent cells were mixed with 1 jlg of uncut, circular pCZR133 or with 1 tg of Not I-digested pCZR133. In three separate experiments, an average of roughly 25 transformants were recovered with circular DNA while linear DNA yielded an average of nearly 1 x 104 transformants. These data indicate that linear DNA transforms P. methanolica with much greater efficiency than circular DNA.
Finally, the relationship between DNA concentration and transformation efficiency was investigated. Aliquots of linear pCZR133 DNA (1 ng, 10 ng, 100 ng and 1 gg in 10 ul H 2 0) were mixed with 100 pl electrocompetent cells, and electroporation was carried out at 3.75 kV/cm and "infinite" ohms. The number of transformants varied from about 10 (1 ng DNA) to 104 (1 gg DNA) and was found to be proportional to the DNA concentration.
Example Integration of transforming DNA into the genome of P. methanolica was detected by comparison of DNA from wild-type cells and stable, white transformant colonies. Two classes of integrative transformants were identified. In the first, transforming DNA was found to have integrated into a homologous site. In the second class, transforming DNA was found to have replaced the endogenous A UG1 open reading frame. While not wishing to be bound by theory, this second transformant is believed to have arisen by a "transplacement recombination event" (Rothstein, Methods Enzvmol. 194:281-301, 1991) whereby the transforming DNA replaces the endogenous DNA via a double recombination event.
P. methanolica ade2 strain #11 was transformed to Ade with Asp I-digested pCZR140, a Bluescript® (Stratagene Cloning Systems, La Jolla, CA)-based vector containing the P.
methanolica ADE2 gene and a mutant of A UGI in which the entire open reading frame between the promoter and terminator regions has been deleted (Fig. Genomic DNA was prepared from wildtype and transformant cells grown for two days on YEPD plates at 30°C. About 100-200 p of cells was suspended in 1 ml H 2 0, then centrifuged in a microcentrifuge for 30 seconds. The cell pellet was recovered and resuspended in 400 gl of SCE DTT zymolyase (1.2 M sorbitol, 10 mM Na citrate, 10 mM EDTA, 10 mM DTT, 1-2 mg/ml zymolyase 100T) and incubated at 37°C for 10-15 minutes. 400 gl of 1% SDS was added, and the solution was mixed until clear. 300 p.1 of 5 M potassium acetate, pH 8.9 was added, and the solution was mixed and centrifuged at top speed in a microcentrifuge for five minutes. 750 l.1 of the supernatant was transferred to a new tube and extracted with an equal volume of phenol/chloroform. 600 l.
1 of the resulting supernatant was recovered, and DNA was precipitated by the addition of 2 volumes of ethanol and centrifugation for minutes in the cold. The DNA pellet was resuspended in 50 ml TE (10 mM Tris pH 8, 1 mM EDTA) 100 gg/ml RNAase for about 1 hour at 65 0 C. 10-pl DNA samples were digested with Eco RI (5 pl) in a 100 pl reaction volume at 37 0 C overnight. DNA was precipitated with ethanol, recovered by centrifugation, and resuspended in 7.5 .1 TE 2.5 gl 5X loading dye. The entire ml volume was applied to one lane of a 0.7% agarose in 0.5 X TBE (10 X TBE is 108 g/L Tris base WO 98/02536 PCT/US97/12582 22 7-9, 55 g/L boric acid, 8.3 g/L disodium EDTA) gel. The gel was run at 100 V in 0.5 X TBE containing ethidium bromide. The gel was photographed, and DNA was electrophoretically transferred to a positively derivatized nylon membrane (Nytran® Schleicher Schuell, Keene, NH) at 400 mA, 20 mV for 30 minutes. The membrane was then rinsed in 2 X SSC. blotted onto denaturation solution for five minutes, neutralized in 2 X SSC, then cross-linked damp in a UV crosslinker (Stratalinker®, Stratagene Cloning Systems) on automatic setting. The blot was hybridized to a PCR-generated A UG1 promoter probe using a commercially available kit (ECLTM kit, Amersham Corp., Arlington Heights, IL). Results indicated that the transforming DNA altered the structure of the A UG1 promoter DNA, consistant with a homologous integration event (Fig. 2).
In a second experiment, P. methanolica ade 2 strain #11 was transformed to Ade+ with Not I-digested pCZR137, a vector containing a human GAD65 cDNA between the AUG1 promoter and terminator (Fig. Genomic DNA was prepared as described above from wild-type cells and a stable, white, Ade+ transformant and digested with Eco RI. The digested DNA was separated by electrophoresis and blotted to a membrane. The blot was probed with a PCRgenerated probe corresponding to either the AUG1 open reading frame or the AUG1 promoter.
Results demonstrated that the AUGI open reading frame DNA was absent from the transformant strain, and that the AUG1 promoter region had undergone a significant rearrangement. These results are consistent with a double recombination event (transplacement) between the transforming DNA and the host genome (Fig. 3).
Example 6 An A UG1 strain of P. methanolica is grown in high-density fermentation conditions.
The fermentation vessel is charged with mineral salts by the addition of 57.8 g (NH 4 )2SO 4 46.6 g KC1, 30.8 g MgSO 4 .7H 2 0, 8.6 g CaSO 4 -2H20, 2.0 g NaC1, and 10 ml antifoam (PPG). H 2 0 is added to bring the volume to 2.5 L, and the solution is autoclaved 40 minutes. After cooling, 350 ml of 50% glucose, 250 ml 10 X trace elements (Table 210 ml of 30% NaPhosphate, 25 ml 200 p.g/ml biotin, and 250 ml cell inoculum are added. Cells are batch-fed glucose or glucose/methanol in three phases. In phase 1, the cells receive 0.4%/L/hour glucose (w/v final fermentation volume) for 25 hours using 750 g glucose, 110 g (NH 4 2 SO4, and 278 ml 10 X trace elements per 1.5 liter.
The cells are then given a transition feed of 0.2% glucose, 0.2% methanol/L/hour for 5 hours. The final glucose-supplemented methanol feed contains 0.1% glucose, 0.4% methanol/L/hr for 25 hours.
Final biomass is about 300 g/L cell paste.
WO 98/02536 PCT/US97/12582 23 Example 7 For fermentation of a P. methanolica auglA strain, the fermentation vessel is initially charged with mineral salts, glucose, phosphate, trace elements and biotin as disclosed in Example 6. 250 ml of cell inoculum is added. A glucose feed is prepared using 600 g glucose, 108 g (NH 4 2
SO
4 and 273 ml 10 X trace elements per 1.2 liter. The cells are batch-fed in three phases.
In the first phase, the cells receive glucose for 12 to 25 hours at 0.4%/L/hour. The cells are then induced with a bolus addition of 1% methanol by weight and transitioned to methanol utilization with a mixed 0.2% glucose/0.1% methanol feed for 10 hours. In the third phase. a mixed feed of 0.2% glucose, 0.2% methanol is delivered for 15 hours.
Example 8 P. methanolica cells in which the AUGI gene had been disrupted by insertion of a expression construct retained the ability to grow on methanol, indicating that a second alcohol oxidase gene was present. The second gene, designated AUG2, was identified by PCR.
Sequence analysis of the 5' coding region of the gene showed that the N-terminus of the encoded protein was similar to those of known alcohol oxidase genes.
Strain MC GAD8, a transformant that grew very poorly on minimal methanol broth, was used as a source for cloning the A UG2 gene. Genomic DNA was prepared from MC GAD8 and amplified with sense and antisense PCR primers specific for the AUG1 open reading frame (8784, SEQ ID NO:5; 8787, SEQ ID NO:6). A product identical in size to the AUG1 product but showing very low intensity on an analytical gel was obtained.
The putative A UG2 PCR product was digested with a battery of restriction enzymes.
Partial digestion by Eco RI and Pvu I, and the presence of several Bgl II sites suggested that the DNA was contaminated with small amounts of AUG]. To remove the contaminating AUG1 DNA, the PCR mixture was cut with Eco RI and gel purified. Since the MC GAD 8 product did not appear to have an Eco RI site, it was unaffected. The resulting gel-purified DNA was reamplified and again analyzed by restriction digestion. The DNA gave a different restriction map from that of the A UG1 PCR product.
Southern blot analysis was performed on genomic DNA from MC GAD8 and wildtype cells using either AUG1 or A UG2 open reading frame PCR fragments as probes. The A UG2 probe hybridized at low stringency to the AUGI locus and at both low and high stringency to a second locus. The A UG1 probe bound to both loci at low stringency, but bound predominantly to the A UG1 locus at high stringency. These data indicated that the new PCR product from MC GAD8 was similar to but distinct from AUG1. Sequence analysis showed an 83% identity between A UGI and A UG2 gene products.
To clone the A UG2 genomic locus, PCR primers were designed from the original AUG2 PCR fragment. Primers 9885 (SEQ ID NO:7) and 9883 (SEQ ID NO:8) were used to screen a P. methanolica genomic library. A positive clone bank pool was then probed with the original MC GAD8 PCR product. Cells were plated on 10 plates at about 5000 colonies/plate and grown overnight, then the plates were overlayed with filter discs (Hybond-N, Amersham Corp., Arlington Heights, IL). Colonies were denatured, neutralized, and UV cross-linked. Bacterial debris was WO 98/02536 PCT/US97/12582 24 washed from the filters with 5X SSC, and the filters were again cross-linked. Blots were prehybridized in pairs at 42 0 C for 1 hour in 25 ml hybridization buffer. Approximately 250 ng of probe was then added to each pair of filters. Hybridization was conducted at 42 0 C for four hours.
The blots were then washed in 500 ml of 0.1 X SSC, 6M urea, 0.4% SDS at 42 0 C for 10 minutes, four times. The blots were then neutralized with 500 ml of 2 X SSC at room temperature for minutes, two rinses. The blots were then immersed in 100 ml development reagent (ECL, Amersham Corp.).
Positive colonies were picked and amplified using PCR primers 9885 (SEQ ID NO:7) and 9883 (SEQ ID NO:8) to confirm their identity. Positive pools were streaked on plates, and single colonies were rescreened by PCR. One colony was selected for further analysis (restriction mapping and sequencing). A partial sequence of the A UG2 gene is shown in SEQ ID NO:9. As shown in SEQ ID NO:9, the AUG2 sequence begins at the HindIII site a nucleotide 91.
Nucleotides upstream from this position are vector sequence. The coding sequence begins at nucleotide 170.
Disruption of the AUG2 gene had little effect on cell growth on methanol. Cells lacking both functional AUG1 and AUG2 gene products did not grow on methanol. Subsequent analysis showed that the A UGJ gene product is the only detectable alcohol oxidase in cells grown in a fermentor.
From the foregoing, it will be appreciated that. although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.
i WO 98/02536 PCT/US97/12582 SEQUENCE LISTING GENERAL INFORMATION: APPLICANT: ZymoGenetics, Inc.
1201 Eastlake Avenue East Seattle, Washington 98102 United States of America (ii) TITLE OF INVENTION: PREPARATION OF PICHIA METHANOLICA AUXOTROPHIC
MUTANTS
(iii) NUMBER OF SEQUENCES: 9 (iv) CORRESPONDENCE ADDRESS: ADDRESSEE: ZymoGenetics, Inc.
STREET: 1201 Eastlake Avenue East CITY: Seattle STATE: WA COUNTRY: USA ZIP: 98102 COMPUTER READABLE FORM: MEDIUM TYPE: Floppy disk COMPUTER: IBM PC compatible OPERATING SYSTEM: PC-DOS/MS-DOS SOFTWARE: PatentIn Release Version #1.25 (vi) CURRENT APPLICATION DATA: APPLICATION NUMBER: FILING DATE:
CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION: NAME: Parker, Gary E REGISTRATION NUMBER: 31-648 REFERENCE/DOCKET NUMBER: 96-17 (ix) TELECOMMUNICATION INFORMATION: TELEPHONE: 206-442-6673 TELEFAX: 206-442-6678 INFORMATION FOR SEQ ID NO:1: WO098/02536 PTLS7128 PCTfUS97/12582 26 SEQUENCE CHARACTERISTICS: LENGTH: 3077 base pairs TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: Genomic DNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi
CAGCTGCTCT
TCCCCAACAG
TATTGATGCT
CTGTGGGCGT
TGATTCTCTT
GMACGCTGAC
TGCTTGCTTA
CTCCTGTAAA
AAMATTGCTA
AMAAGAATGA
GCIAAATCTGT
TTTGCGGGTA
CCATGAGTGT
TTCTTTCCMA
SEQUENCE DESCRIPTION: SEQ ID NO:1: GCTCCTTGAT TCGTAATTMA TGTTATCCTT TTACTTTGAA CTCTTGTCGG
GGATTCCAAT
GCAAAAACTT
TCCACACTCC
ATTACCAGTT
CCACGGTTTC
AAGCGGCTAA
GGGCCGATTC
MGGAGTACT
CGCTGTATGT
TGGTCACCGG
GGAAGCMAGG
TTCCCTCTGG
GTTCGGCTTT
CGGTGCTCAG
TTTTAGCCGG
TTGCTTTTCA
ATGTAGAMAG
MAATMACTAT
AAAGTGTTTG
GACTTCGAAA
AGGGCTGTAG
CGTAGCCTGC
TTCGATCCGG
TCTAGTTTTC
CTACCTAATA
CAGCTCGTMA
CGGGATTTCC
GTTTAAGTAA
TAATCTCTGT
ATCGGCAAAC
CAGMACTCTA
GCAAATTkAAA
GAGCCTAA
TAATAMATM
ACGAGTAGCT
TCTCGGGCTT
GTCGTTTCGG
TATTTATTGA
ATGTGCAAGA
CATGAGGTTT
CTGGGCAATA
GTATTGTTTT
AAAATATCAA
TAGCTATAGG
AAAGCTGTGA
ACAGTGACTA
TGGAACAGTG
CAGTGGTAGA
CCTTTTTTGC
ATGGTTTACG
TCGGTCTCTC
AATATTTGAC
TTGACAACTT
TTTCCAAAGG
ATTCGCATTT
CTTTTATCTI
GGAAGTTTAC
CAAGTAGGAA
TTGGTGACGG
GTACAACMAT
GCAGCAGATT
TTTTTCGATA
AAAGTATCAG
ATGTGAATGT
TCCAGCGACC
120 180 240 300 360 420 480 540 600 660 120 780 840 900 TTTCAGAGTC AAATTAATTT TCGCTAACMA TTTGTGTTTT TCTGGAGAAA CCTAAAGATT WO 98/02536 PTU9/28 PCTfIJS97/12582
TMACTGAIMA
TATTAACCMA
TGTCGGGATT
GAATATCA
TTTAGATGAC
CMAGTGIGAT
ICAAAAGGCA
TAATACTTG
TGITGAAAGT
GCTAAAATCT
ATATATACCT
TCCATTTTCA
CTACCCAACT
TAGAGTIAAC
TTTCCCAGGT
AGICAACGMA
CACCTCGCAA
CACTTGT'TTG
GCAAAACGGT
CITATACGGT
ATCMATGACI
TCTCGMAGAA
GTCGMITCAA
TAGCATAIIC
TTAGGTGGTG
ACTGTGATTC
CAIATIGACG
GTTTIMACCG
ACTGGCATCA
CAAAAAGAGC
AGCGCAGCAT
AGAACMATGG
GAAGCTTTGA
PAGGAGITAG
GTTGMAACCA
GATACTGTCC
GCIOGTAICT
ATTGCCCCAA
TTTGAAGCTC
TCGACTCCAT
GAGTICAAGA
MAGACTACAA
GACTGIGAGC
CAGTACACIA
CATCTTTAA
ACAGGCATCA
GCCMACTTGG
ICGAAAATGG
GCTCATTCMA
TTGAGATTGA
AAATCTTCCC
ATTTGATTAA
CTTIAGAAGA
CCTATGACGG
AAGTTTTAGA
CTGTTATGGT
ICCACCAAAA
AAAAGAAGGC
TTGGTGTTGA
GACCTCACAA
ATGITAGGGC
CTACCCAAGC
TGTGTIAAAAG
GACCAGGCAG
GTAGATTACA
CAGATTCCAT
TCCTAGTT
CATCGGAACA
TCGTATGATC
AGACCAGGCT
TGATCCAAAA
ACATGTIGAC
ATCACCAGAA
GAATGGCATT
AGTTGGTGCC
MAGAGGTAAT
TGACAGGCCG
TGTGAGATCA
CAACATCIGT
CCAAATTTTG
AATGTITTTA
TTCTGGTCAC
CATTFACTGGT
TATTATGTTG
AGCACTAGAA
AAAAATGGGT
TTACATAGMA
ICCGGGCACT
MAGATCTCTG
TTCAGMATGG
GTTGAAGCTG
CCAGCAAAGC
GCAATTGCCG
ACIGATGCGT
ACTATCAT
GCTGTTGCCG
AAATACGGCT
ITTGITGTCA
TTATACGCCG
ATCGATGGCC
CACACTGTCT
GCTGACAACG
TTACAAAATG
TATACCATCG
CTACCCATGC
AACG1FAG
ACTCCTCATG
CACATTAATA
GGTACGACTA
TCMAGCAAGC
CAGCGGCCAG
ACTCGCAAAC
CACACAGATT
MATCAACGC
AATTGGCTGC
TGGTTGAAGT
IGATCAAAGA
MTCTIGTAG
TCCCATACAT
AAGACAAGTC
AGAMATGGGC
MGTTTFATTC
TTGCTCCAGC
CTGTCAMATC
GTGACTTATT
ACGCTTGTGT
CGMAGAACTT
GTGGCGATGA
CTTCTGTTTA
TAG1TTCTCA
ACAGCATCCC
CATTAGTCGG
960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1620 1680 1740 1800 1860 1920 1980 2040 2100 2160 2220 WO 98/02536 PCTIUS97/12582
TGTCATCATG
GCAATTTMAC
GGCCAAGTAT
TGGTGCCGCT
CCCTGTTA
MAGAGGTATT
TATCACMATC
AATATGGAAA
TACTTGAGTA
TTAATTGTTC
TTGAMATTTC
ACAATMATAT
AGATATTGCT
CACAAAAATT
ACACCTMATA
GGTTCCGATT
GTTCCATTTG
GCCATTGATG
CATTTACCGG
GGCTCTACTT
CCTGUTGCTA
TTAGGTGCCG
ATGAAGTTTT
CATACAAGMA
TMACTGTTAA
TAGTTGCTCG
ATTATVCMA
AGCGCUTATC
TTCCGMACCT
CCTGCAG
CGGACCTACC
MGTCACTAT
CTCCAAAGAG
GIAATGGTTGC
TGGATGGTGT
CTGTGGCTAT
GCGATCCAAA
GGGCMAGGCT
GTAGAACCTT
TTTCTGCTTT
TMGAGGAAA
CACTGCTATA
ATTATCCTTA
GTTTTTCACT
AGTCATGTCT
CGTTTCCGCT
AGGGTTGMAG
GGCGATGACG
TGATTCACTA
TAACMATGCT
TACTTGTCTG
GAAAAATTGG
TTATATTTGA
GCATTTCTGA
CTTGCATTCA
TGGTAGTTTT
ATTGTTCATC
TCTCCAGATC
CTAGGTTGTA
CATAGMACCC
TGCATCATTG
CCGCTGCCTG
CACTCCATCG
ACTAACGCTG
CAATGGMAGT
AAAATGGTGG
TATAGTACTT
AMAGTTTAAG
AATAACATTA
ATAGGTTTGG
GACGCAAATC
TTGGTTTAGT
ATATATTGAA
CACAAAGMAT
CTGGTGCTGG
TTATTGGTGT
TTCAAATGCC
CCTTGCTAGG
TTATATGMAC
ATATGAAGMA
ACTCAAAGTC
ACAAGAAATC
ACAATAAATG
TIAGGATTIG
GACGCATTTC
ATAGCTTTTG
2280 2340 2400 2460 2520 2580 2640 2700 2760 2820 2880 2940 3000 3060 3077 INFORMATION FOR SEQ ID NO:2: SEQUENCE CHARACTERISTICS: LENGTH: 3386 base pairs TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: Genomic DNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO FRAGMENT TYPE: (vi) ORIGINAL SOURCE: WO 98/02536 PCTIUS97I 12582 29 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: GAATTCCIGC AGCCCGGGGG ATCGGGIAGT GGAATGCACG GTTATACCCA
AAGTGTAGTA
CCCTMATCTG
GGGGCAGCAT
AAGTTTTATC
MACTCAAAT
GTTTTGTTAA
ACACTTTCCT
TGTGGGGACA
CAAGACAAAA
AGGCAGGCAG
TTCAAATAAC
GATCCATCAC
GCTCCTTCAA
AAAG]TVTAT
CCGCTCTCTC
CTCCGTGTAC
TTCTFGAA
TCMACCITGI
TTACCMATA
ACAMTGTT
GCCGGACTGA
TTAACAGTCT
CGAGACTCGA
TGTTTTTAGA
TAATGGAAAT
ATGACTATCG
GCTTGCTGGT
CITGACATCT
CAACCCTTTG
GCAGGCAGCG
AGCCTGCTGC
CTTTTGTCGT
TMTTAAATC
CTCTATGGCC
TTTACCCCAG
AAGCGGAGCT
ACTCTTGGTC
TCMACATTCT
AICAATCTTC
TAAACCAACT
AAGGTTTTAG
CGGAGTATAC
GATGGIACAI
AUMAAAGAC
AGCCTGTTTT
AACAAGCCAT
TGACTCTCCT
CACATGCACC
ICCTGCTCTT
GGCTGCCTGC
TATCTGTGAC
ACICCGACMA
AAATAAGCAT
MCGGATAGT
ATTCTCAAAG
TTTGCCTCCC
AAATCAAATC
ATAAATCGAT,
MAATTTCAAA
ATIAACTTTTA
GAGTCTGTTI
MAAAAAGTAA
ACTTAAAAGC
GATTGTTGTA
GAAAAMTACA
GAAATAGCAC
CATACAAACA
CCAGATTAAT
TTCTTTCTCA
CATCTCIT
CAGATTGGGA
TGATCCTTCC
AAMTAGTPAAA
CTATCTGCTT
CTMITATCTG
ATCCTCTTGC
AAACAAMACC
ATAMATATM C
TATT-FCTAC-
ACTGGCTTTA(
GTTTGTTCAT
GTCAAATATC
TGCCATATTG
ACMAACGTT
CCTTCTTMAG
ATITCTGCCA
CCCAAAAGGG
TTCCCCAGAC
CACCGCGIGG
CGCTGCTCCT
CACCCCCCTC
CTGTCATCTT
ATCGCATACA
AATTCCATCC
CCCCTTGTCT
JTVGTTTCGG
AAACCTTCTA
CCTTATCCCT
VTGCTTTAT
3AAGTTTAT
CTCCAAATAA
GTGCATCATT
AAGGTGGCCG
AGGIAACTTCA
GTGCCTACAT
TACTGACAAA
GTCACTTTTA
MAACTTTCAG
GATGCGGAGA
GTGTGTGCGC
CCCCCCTGGC
CCCTCCGMAT
CTGGCAATCA
AACGTCATGA
ACTTTGGGMA
ATTGTCCTTT
TTATTTTTTT
TTCCATCAGA
CCCTTG1TV
ACTCAGTATT
TTAACATCAG
120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 WO 98/02536 PCTIUS97/12582
TTTCAATTTFA
TACGAAAAAA
TATTGTTGIC
CGMAAACGIC
TTACTTACCA
CTCTTCMAGA
CTIGGGIGGT
CGATGATTGG
TGAMACTTAT
GGTTTCATTT
TCMAGGTATT
CTGGITGMAG
TCACCCMACC
GATIATCATT
TTCTCCAAAG
TGGTACTATC
GAGACAAGTT
TCACTACTGT
TGTIAGAGGI
TGGTCCATTA
ATTAGCCACT
AGATAAGCCA
CATCTTTATT
AAATCTTACT
GGTGGTGGTT
ACAGTTGCTT
GGTGTTIATC
CCATCAGCAC
GGTTCTTCCA
GMITCTGMAG
CAAAGACCAT
GGTAACTATA
CCATTTGITG
TGGATCAACA
ATGAGMAACA
GAAAACGGTG
ACCCAAGTTG
TCAICACCAT
GGTATTAAAC
TTCTICACTC
GATAAAGCTG
ACCACTMATG
GCTGATGACG
TTAATGCACT
TATIAACGAA
ATTMATTTCI
CCACCGGTTG
TAATCGAAGG
CAAGAAACAT
ACTTGMACGG
TCAACTTCTT
GTTGGACTAC
GTMACAACAG
CTTATCCAAA
ATGATGCTGA
GAGACTIAGG
AGCAP4AACTT
TTGCIACIGG
CTAGAACTTT
TAGTFYGCA
CMATTGTTGA
CATACCATGT
TTCAAMAATC
GTATTGAGGC
MTTCAGAGC
ACTCTCTAAT
ATCTTTACGA
CAAAATGGCT
IGCTCTTGCT
IGGTGMPAAC
GAGATTAGAC
TAGMAGAGCT
GATGTACACC
CGATGMATTA
AGMATTGCAC
CGGTCAAGAT
AGATTTGAMA
TAGAAGATCC
GTTCTTGATT
TGTTMAGACT
CAAGGCTAGA
AAGATCTGGT
CITACCAGGT
CMGCCAGAT
TGCTTTCGAC
AGGTGTTMAG
TGCTTATGAT
TTCTGGTTTC
ATTAACTCMA
ATTCCAGATG
GGTAGATTAG
.AACATCAACA
TCAAAGACTG
ATTGTTCCAI
AGAGCCICTG
TTACCACTMA
GGTTTCGATG
TTFCATTAGAG
IGTTCCCACG
GATTCTGCTC
ACTICCACCA
GTTCCAATGA
AAGCMAATTA
ATCGGITCCG
GTTGGTATGA
ACTCCATCAT
CAATGGTATG
ATTAGACCAA
GACTACTTTG
MTGGTGACC
TCAAMAC1TT
AATTTGATAT
GTAACTTGGA
ACCCATGGGT
CTACTTTTTA
GTGCTMACAT
CCTCCGATTA
TGAAGMAGAT
GICCMATTM
CTGCCGMATC
GTGCTGAGCA
ATGCTTACAT
AGTGTGAA4
AGCCAACTGG
TTG1TVCTTG
CTCACAAGTT
ACTTCCMAGA
TCGATGACTT
CTMACMGGA
CTGIAAGMAGA
GIAACAAGCC
ACACCMAGAT
1320 1380 1440 1500 1560 1620 1680 1740 1800 1860 1920 1980 2040 2100 2160 2220 2280 2340 2400 2460 2520 2580 WO 98/02536 PTU9/28 PCTf[JS97/12582
TCCAMACGGT
CGTTCACGTT
CGATCCAAGA
AAGAATGGAC
ACCAGCCAGA
CTTTACTGCT
GAACGCTGCT
GGAGGATGAT
TCTTGGTACT
TGTTGACTCC
TTGCCCAGAT
TTCTACCTTA
MACTTCAAA
TGGATATTTT
AAGTACATGT
GTTTCTCCMA
GATATGTGGC
TGTTTTGCCG
GCTGCTGACA
AACTTGTACC
CACGTTACTT
GCTGCTATCG
TGTTCIAATGG
AGATTAAACG
AATGTTGGTT
GTTGCTGAAG
TTGGGTACTT
TATAATTTTT
GCATGTTCCA
ACCCATACGA
CMATGGTTTG
GTGAAGTTAC
TGGACTTGGA
ACGGTTCATG
CTAACCAAGT
AAGATTACAT
CTCCMAGAGA
TTTACGGTGT
GTIAACACTTA
ACTTGGGCTA
ATGMAGAAGC
GAGAGT
CTTCTTGGMA
TGCTCCTGAC
GTCTTACAAG
TTCTCACCAC
AACTACTAAA
GACTGTTCCA
TGAAAAACAT
CAGAGMACAC
AGGTTCTAAG
TGAAAAGTTG
CTCTACTGCT
CTCTGGTGAT
TGGTCTAGCT
TATCCATTCT
TTTGATCCAG
MGTCCAGAG
CCACACTACC
GCTTATGCTG
ATTGAAAAGC
CGTGACATCG
ACTGAAACCA
GTTGTCCCMA
MGGTTGCTG
TTGTTMATCG
GCTTTGMAGA
AGATTCTAGG
CCAGAGGT-TT
GTTTCATGAA
AAACTGCCAG
CATACGACTC
GTCCAGACCA
CAACTCCA
MATACACCMA
CATGGCATTG
CTGGTGGTGT
ATTTATCAAT
GTGAAAAGGC
TGACTGTTCC
GCTGCCTGTT
2640 2700 2760 2820 2880 2940 3000 3060 3120 3180 3240 3300 3360 3386 INFORMATION FOR S[Q ID NO:3: SEQUENCE CHARACTERISTICS: LENGTH: 38 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: TGATCACCTA GGACTAGTGA CMAGTAGGAA CTCCTGTA WO 98/02536 WO 98/02536 PCT/US97/12582 32 INFORMATION FOR SEQ ID NO:4: SEQUENCE CHARACTERISTICS: LENGTH: 39 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: CAGCTGCCTA GGACTAGTTT CCTCTTACGA GCAACTAGA 39 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 17 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID TGGTTGAAGT GGATCAA 17 INFORMATION FOR SEQ ID NO:6: SEQUENCE CHARACTERISTICS: LENGTH: 17 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: GTGTGGTCAC CGAAGAA 17 INFORMATION FOR SEQ ID NO:7: SEQUENCE CHARACTERISTICS: LENGTH: 24 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear WO 98/02536 PCT/US97/12582 33 (vii) IMMEDIATE SOURCE: CLONE: ZC9885 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: GTTGTTCCTT CCAAACCATT GAAC 24 INFORMATION FOR SEQ ID NO:8: SEQUENCE CHARACTERISTICS: LENGTH: 24 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (vii) IMMEDIATE SOURCE: CLONE: ZC9883 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: AAAGTAAGAA GCGTAGCCTA GTTG 24 INFORMATION FOR SEQ ID NO:9: SEQUENCE CHARACTERISTICS: LENGTH: 329 base pairs TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: GACCATGATT ACGCCAAGCG CGCAATTAAC CCTCACTAAA GGGAACAAAA GCTGGGTACC GGGCCCCCCC TCGAGGTCGA CGGTATCGAT AAGCTTTATT ATAACATTAA TATACTATTT 120 TATAACAGGA TTGAAAATTA TATTTATCTA TCTAAAACTA AAATTCAAAA TGGCTATTCC 180 WO098/02536 PCTIUS97/12582 34 TGAAGMATTC GATATCATTG TTGTCGGIGG TGGTTCTGCC GGCTGICCTA CTGCTGGTAG 240 ATTGGCTMAC TTAGACCCMA ATVMACTGT TGCTTTAATC GMGCTGGTG AAAACAACAT 300 TMACAACCCA TGGGTCTACT TACCAGGCG 329
Claims (11)
1. A method for preparing Pichia methanolica cells having an auxotrophic mutation comprising: exposing P. methanolica cells to mutagenizing conditions; culturing the cells from step in a rich medium to allow mutations to become established and replicated in at least a portion of said cells; culturing the cells from step in a culture medium deficient in assimilable nitrogen to deplete cellular nitrogen stores; culturing the cells from step in a defined culture medium comprising an inorganic nitrogen source and an amount of nystatin sufficient to kill growing P. methanolica cells to select for cells having a deficiency in a nutritional gene; and culturing the selected cells from step in a rich culture medium.
2. A method according to claim 1 wherein the selected cells from .step (e) are replica plated to a defined medium and cultured to confirm the presence of an auxotrophic mutation.
3. A method according to claim 1 wherein the selected cells are auxotrophic for adenine.
4. A method according to claim 3 wherein the selected cells are deficient in phosphoribosyl-5-aminoimidazole carboxylase.
A method according to claim 1 wherein the defined culture medium contains 2 mg/L nystatin.
6. A method according to claim 1 wherein the mutagenizing conditions comprise exposure to ultraviolet light.
7. A method according to claim 1 wherein the mutagenizing conditions comprise exposure to a chemical mutagen.
8. A method according to claim 1 wherein the inorganic nitrogen source comprises ammonium ions. b 36
9. A method according to claim 8 wherein the inorganic nitrogen source is ammonium sulfate.
A method for preparing Pichia methanolica cells having an auxotrophic mutation substantially as hereinbefore described with reference to any one of the s Examples.
11. Pichia methanolica cells having an auxotrophic mutation prepared by the method of any one of claims 1 to Dated 4 February, 1999 ZymoGenetics, Inc. Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON 00 o e 0o oo O O 1 o ooo o [n:\libc]00204:drg
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68350096A | 1996-07-17 | 1996-07-17 | |
| US08/683500 | 1996-07-17 | ||
| US08/703,808 US5736383A (en) | 1996-08-26 | 1996-08-26 | Preparation of Pichia methanolica auxotrophic mutants |
| US08/703808 | 1996-08-26 | ||
| PCT/US1997/012582 WO1998002536A2 (en) | 1996-07-17 | 1997-07-14 | Preparation of pichia methanolica auxotrophic mutants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3885697A AU3885697A (en) | 1998-02-09 |
| AU708572B2 true AU708572B2 (en) | 1999-08-05 |
Family
ID=27103122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU38856/97A Ceased AU708572B2 (en) | 1996-07-17 | 1997-07-14 | Preparation of (pichia methanolica) auxotrophic mutants |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP2002514049A (en) |
| CN (1) | CN1238806A (en) |
| AU (1) | AU708572B2 (en) |
| CA (1) | CA2261020C (en) |
| IL (1) | IL128072A0 (en) |
| WO (1) | WO1998002536A2 (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69941126D1 (en) | 1998-09-23 | 2009-08-27 | Zymogenetics Inc | CYTOKINEREZEPTOR ZALPHA11 |
| US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
| SI1642972T1 (en) | 1999-01-07 | 2010-05-31 | Zymogenetics Inc | Therapeutic uses of BR43X2 soluble receptors |
| KR100743640B1 (en) | 1999-03-09 | 2007-07-27 | 지모제넥틱스, 인코포레이티드 | New Cytokine JALLPHAA Ligand |
| EP2241623A3 (en) | 1999-07-07 | 2010-12-01 | ZymoGenetics, Inc. | Monoclonal antibody against a human cytokine receptor |
| AU2292601A (en) | 1999-12-23 | 2001-07-03 | Zymogenetics Inc. | Novel cytokine zcyto18 |
| CA2412239C (en) | 2000-06-26 | 2013-05-28 | Zymogenetics, Inc. | Cytokine receptor zcytor17 |
| WO2002066516A2 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| BRPI0209933B8 (en) | 2001-05-24 | 2021-05-25 | Zymogenetics Inc | fusion protein, and, nucleic acid molecule |
| ES2411007T3 (en) | 2001-10-10 | 2013-07-04 | Novo Nordisk A/S | Remodeling and glycoconjugation of peptides |
| ES2334338T3 (en) | 2001-11-05 | 2010-03-09 | Zymogenetics, Inc. | IL-21 ANTAGONISTS. |
| EP2840089A1 (en) | 2002-01-18 | 2015-02-25 | ZymoGenetics, Inc. | Cytokine receptor zcytor17 multimers |
| DK1961811T3 (en) | 2002-01-18 | 2010-11-08 | Zymogenetics Inc | Cytokine ligand for the treatment of asthma and respiratory hyperresponsiveness |
| CN1659274A (en) | 2002-04-19 | 2005-08-24 | 津莫吉尼蒂克斯公司 | cytokine receptor |
| PL1615945T3 (en) | 2003-04-09 | 2012-03-30 | Ratiopharm Gmbh | Glycopegylation methods and proteins/peptides produced by the methods |
| WO2006013072A2 (en) | 2004-08-02 | 2006-02-09 | Basf Plant Science Gmbh | Method for isolation of transcription termination sequences |
| CN100347287C (en) * | 2004-09-30 | 2007-11-07 | 汪和睦 | Recombinated multi shape ttansenula yeast, its structural method and application |
| EP1856156A2 (en) | 2005-02-08 | 2007-11-21 | ZymoGenetics, Inc. | Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation |
| EP1891107B1 (en) | 2005-05-12 | 2011-07-06 | ZymoGenetics, Inc. | Compositions and methods for modulating immune responses |
| EP1922080A2 (en) | 2005-08-09 | 2008-05-21 | ZymoGenetics, Inc. | Methods for treating b-cell malignancies using taci-ig fusion molecule |
| WO2007019573A2 (en) | 2005-08-09 | 2007-02-15 | Zymogenetics, Inc. | Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules |
| JP2009510093A (en) | 2005-09-28 | 2009-03-12 | ザイモジェネティクス, インコーポレイテッド | IL-17A and IL-17F antagonists and methods of use thereof |
| BRPI0711823A2 (en) | 2006-05-15 | 2012-01-17 | Ares Trading Sa | methods for treating autoimmune diseases with a taci-ig fusion molecule |
| WO2009065415A1 (en) | 2007-11-21 | 2009-05-28 | Roskilde Universitet | Polypeptides comprising an ice-binding activity |
| KR101720760B1 (en) | 2008-01-25 | 2017-03-28 | 오르후스 우니베르시테트 | Selective exosite inhibition of papp-a activity against igfbp-4 |
| ES2410579T5 (en) | 2008-12-16 | 2021-10-04 | Novartis Ag | Yeast deployment systems |
| EP3597764A3 (en) | 2012-02-01 | 2020-05-06 | SGI-DNA, Inc. | Material and methods for the synthesis of error-minimized nucleic acid molecules |
| WO2014202089A2 (en) | 2013-06-18 | 2014-12-24 | Roskilde Universitet | Variants of anti-freeze polypeptides |
| CN111157680B (en) * | 2019-12-31 | 2021-10-26 | 北京辰安科技股份有限公司 | Indoor volatile substance leakage tracing method and device |
| CN116064597B (en) * | 2023-01-17 | 2024-04-26 | 北京大学 | Directed evolution and darwinian adaptation in mammalian cells by autonomous replication of RNA |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965389A (en) * | 1995-11-09 | 1999-10-12 | Zymogenetics, Inc. | Production of GAD65 in methylotrophic yeast |
-
1997
- 1997-07-14 JP JP50632398A patent/JP2002514049A/en not_active Ceased
- 1997-07-14 AU AU38856/97A patent/AU708572B2/en not_active Ceased
- 1997-07-14 IL IL12807297A patent/IL128072A0/en unknown
- 1997-07-14 WO PCT/US1997/012582 patent/WO1998002536A2/en not_active Ceased
- 1997-07-14 CN CN97197503.5A patent/CN1238806A/en active Pending
- 1997-07-14 CA CA002261020A patent/CA2261020C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1238806A (en) | 1999-12-15 |
| WO1998002536A2 (en) | 1998-01-22 |
| IL128072A0 (en) | 1999-11-30 |
| AU3885697A (en) | 1998-02-09 |
| WO1998002536A3 (en) | 1998-02-26 |
| CA2261020A1 (en) | 1998-01-22 |
| JP2002514049A (en) | 2002-05-14 |
| CA2261020C (en) | 2004-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU708572B2 (en) | Preparation of (pichia methanolica) auxotrophic mutants | |
| US5736383A (en) | Preparation of Pichia methanolica auxotrophic mutants | |
| US5888768A (en) | Compositions and methods for producing heterologous polypeptides in Pichia methanolica | |
| US5716808A (en) | Genetic engineering of pichia methanolica | |
| CA2237120C (en) | Compositions and methods for producing heterologous polypeptides in pichia methanolica | |
| AU718510B2 (en) | Transformation of pichia methanolica | |
| US5854039A (en) | Transformation of pichia methanolica | |
| US6153424A (en) | Protease-deficient strains of Pichia methanolica | |
| US6001597A (en) | Compositions and methods for producing heterologous polypeptides in Pichia methanolica | |
| EP0946734B1 (en) | Preparation of pichia methanolica auxotrophic mutants | |
| WO1999014347A1 (en) | PROTEASE-DEFICIENT STRAINS OF $i(PICHIA METHANOLICA) | |
| EP1015577B8 (en) | Chromosomal mutagenesis in pichia methanolica | |
| Wong et al. | Increased expression and secretion of recombinant α-amylase in Saccharomyces cerevisiae by using glycerol as the carbon source | |
| US6183953B1 (en) | Chromosomal mutagenesis in Pichia methanolica | |
| US6613547B1 (en) | Pichia methanolica glyceraldehyde-3-phosphate dehydrogenase 1 promoter and terminator | |
| EP0920525A1 (en) | TRANSFORMATION OF $i(PICHIA METHANOLICA) | |
| US6348331B1 (en) | Pichia methanolica glyceraldehyde-3-phosphate dehydrogenase 2 promoter | |
| JP2002537795A (en) | Hansenula polymorpha mutant and method for producing recombinant protein using the same | |
| DE69735369T2 (en) | PREPARATION OF AUXOTROPHIC MUTANES FROM PICHIA METHANOLICA |